Our Companies

Our Accomplishments

› CanChew® Gum is the first CBD hemp oil chewing gum, created using AXIM® Biotechnologies patent for chewing gum as a delivery method for cannabinoids.

› CanChew® Gum has been featured by FOX News Health, Newsweek Magazine, Dr. Oz’s The Good Life Magazine, and Reader’s Digest.

 

Latest CanChew® Biotechnologies News

Report by SeeThruEquity on AXIM® Biotechnologies Details Company’s Immense Potential

AXIM® Biotechnologies received coverage initiation from SeeThruEquity, a leading independent equity research firm focused on smallcap and microcap public companies. The report, released May 10th, reveals AXIM®’s unique position within the nutraceutical and pharmaceutical spaces, recent news from the company’s product development, and the estimated market value of the cannabis industry. The cannabis industry has […]

SeeThruEquity Initiates Coverage On Medical Marijuana, Inc. Investment Company AXIM Biotech (OTC: AXIM) With A Target Price Of $17.00

SAN DIEGO, May 17, 2017 — Medical Marijuana, Inc. (OTC PINK:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM) received coverage initiation from SeeThruEquity, a leading independent equity research firm focused on smallcap and microcap public companies, with a price target of […]

The Exciting Future of Cannabinoid Chewing Gum

Medical Marijuana, Inc. investment company AXIM® Biotechnologies is revolutionizing the way you think about chewing gum with their line of cannabinoid-infused gum. The company is entering clinical trials for a number of formulations of their functional chewing gum for conditions like irritable bowel syndrome and the pain and spasticity associated with multiple sclerosis. With the […]

AXIM® Biotechnologies Starts Phase II Clinical Trial for IBS Treatment

Medical Marijuana, Inc. investment company AXIM® Biotechnologies has announced it has completed enrollment of the required 40 patients for its Phase II clinical trial for CanChew Plus® CBD gum for the treatment of irritable bowel syndrome (IBS) and has commenced the start of the research with an anticipated return of the results this spring. In [...]